Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD), reported Microdose. 

Assuming positive results, Compass will work with the FDA to help legalize psilocybin for TRD treatment, possibly as early as 2025.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.